The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension drug.

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...

Investing.com -- Shares of CVS Health Corp (NYSE:CVS), Cigna (NYSE:CI) Group, and UnitedHealth Group Inc (NYSE:UNH) were down around 1% after the Federal Trade Commission (FTC) accused their ...

The FTC prioritized testimony from drugmakers and pharmacies, industries that benefit from weakening PBMs, said David Whitrap, vice president of external affairs at CVS Health. Need a break?

(Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth ... in “excess” revenue over six years, the Federal Trade Commission said in a report on the drug middlemen.

The Big Three PBMs have largely criticized the FTC report. A spokesperson for CVS Health argued that the FTC has drawn broad conclusions from “cherry-picked” specialty generic outliers in both ...

CVS Health, UnitedHealth Group and Cigna share prices dipped midday after the FTC released its report, but each company rebounded and was up slightly when the New York Stock Exchange closed Tuesday.

Evercore ISI raised the firm’s price target on CVS Health (CVS) to $65 from $60 and keeps an Outperform rating on the shares. Given 2025 will ...

(Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth Group ... bringing in more than $7.3 billion in “excess” revenue over six years, the Federal Trade Commission said in a report on ...